Chronic headaches: from research to clinical practice by unknown
Introduction
When we consider chronic daily headache (CDH), we
refer to a heterogeneous group of headaches whose com-
mon characteristic is its chronicity. There is consensus to
use the term “chronic daily headache” to refer to hea-
daches occurring 15 or more days per month, including
those associated with medication overuse.
Epidemiology
The first population-based studies on CDH have been
published in recent years [1, 2]. In these population-based
surveys, primary CDH occurs in approximately 4%–5% of
the general population (Spain 4.7%, US 4.1% and China
(elderly) 3.9%). In population samples, chronic tension-
type headache (CTTH) is the leading cause of primary
CDH with a one-year period estimated prevalence of 2.2%
in Spain and in the United States, and 2.7% in China [1].
Epidemiological data are different when analysing the dis-
tribution of CDH patients that account for consultation in
headache clinics. In subspecialty practices, CDH evolves
from an episodic headache disorder in over 92% of cases,
usually migraine (72% of cases), and from episodic ten-
sion-type headache (ETTH) in only 20% of the patients.
CDH appears without history of previous headache and is
unremitting from onset in about 8% of cases (NDPH). In
headache clinic groups, the proportion of women is even
higher with a female-male ratio of 4.6:1 [3].
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Abstract Chronic daily headache
(CDH) is a heterogeneous group of
headaches that includes primary
and secondary varieties. Primary
CDH is a frequent entity that prob-
ably affects 4–5% of the popula-
tion. It can be subdivided into
headaches of short duration (<4
h/attack) like chronic cluster
headache, and disorders of long
duration (>4 h/attack). Primary
CDH of long duration includes
transformed migraine, chronic ten-
sion-type headache, and new daily
persistent headache and hemicrania
continua. Analgesics, ergots and
triptan overuse are frequent in all
types of CDH. We revise recent
insights into the epidemiology,
pathophysiology, clinical character-
istics and prognosis of CDH.
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Pathophysiology
Different mechanisms are involved in the development of
CDH. In these patients there is an altered central sensiti-
sation which is manifested by increased spontaneous
impulse discharges, increased responsiveness to noxious
and non-noxious peripheral stimuli, and expanded recep-
tive fields of nociceptive neurons. Migraine patients
evolve a sensitisation of the trigeminal nucleus caudalis
neurons caused by frequent vascular input due to frequent
attacks, which may explain the development of CDH [4].
The enhanced neuronal responses represent a state of cen-
tral sensitisation and, in addition, the cardiovascular
response threshold to facial and intracranial stimuli is
reduced, representing a state of intracranial hypersensitiv-
ity and cutaneous allodynia [5]. Migraine patients who
had allodynia ipsilateral to the headache were significant-
ly older than those who did not, hinting at a possible cor-
relation between age and sensitisation. These findings
provide a neural basis for the pathophysiology of migraine
pain and suggest a basis for continued head pain.
In CTTH a central sensitisation appears, generated by
prolonged nociceptive input from the periphery, particu-
larly from myofascial tissues. Nitric oxide (NO) is
involved in the development of this central sensitisation
and it has been recently demonstrated that NO synthase
inhibition has an analgesic effect in CTTH patients; this
effect could be related to reduction in muscle hardness
that could cause succeeding reduction of central sensitisa-
tion [6].
A down-regulation or suppression of an already partly
suppressed or abnormal antinociceptive system also
appears, particularly in individuals with analgesic
overuse. The “rebound headache” does not appear in non-
headache sufferers who use daily analgesics for another
ailment such as arthritis pain, expressing an inherent vul-
nerability in the primary headache population that predis-
poses them to drug-induced headache.
Genetic factors should be considered in CDH. The
genetic vulnerability of primary headaches is well known
and has been demonstrated in a number of CDH patients [7].
Imaging
One very interesting paper has shown, using a special
MRI sequence, that iron homeostasis in the periaqueduc-
tal grey matter (PAG) was progressively impaired in pati-
ents with chronic or frequent migraine and possibly cau-
sed by repeated migraine attacks. These results emphasise
the possible role of changes in the central pain structures
as a possible cause of pain chronification [8].
Comorbidity
Anxiety, depression, sleep disturbances and medication
abuse are frequent in patients with CDH. In headache suf-
ferers there is a correlation between high headache attack
frequency, a long history of headaches and female sex,
and rating elevation for both anxiety and depression.
Patients with CDH show increased anxiety levels in all,
and hysteric traits in some. With time, they may develop a
depressive disorder.
Drug overuse
Drug abuse is frequent in CDH patients. Different mecha-
nisms probably contribute to its development. Psycho-
logical factors include the reinforcing properties of pain
relief by drug consumption, a very powerful component of
positive conditioning. Withdrawal headache is an addi-
tional problem, because whenever the patient tries to stop
or reduce the medication, he experiences a worsening of
the headache. Analgesic drugs also have psychotropic side
effects such as sedation or euphoria that may stimulate
drug dependency [9].
The actual dose limits and time needed to develop
rebound headaches have not been defined in rigorous stud-
ies, but there is a consensus of the approximate doses [10].
Patients can overuse analgesics, ergots and opioids. In
recent years, triptans have shown they could lead to drug-
induced headache in patients with or without a previous
history of analgesic overuse. The weekly dosages and the
time of onset necessary to initiate triptan misuse-induced
headache may be lower with the newer centrally penetrant
triptans than with ergots or sumatriptan. The alarm sign of
overuse is the progressive increase of attack frequency.
Clinical presentation
CDH comprises a heterogeneous group of headaches
whose common characteristic is their chronicity. The term
“chronic daily headache” only refers to the frequency of
headache that appears 15 or more days per month, includ-
ing those associated with medication overuse.
Chronic migraine
Following the last IHS classification, chronic migraine is
a migraine headache occurring on 15 or more days per
177
month for more than 3 months in the absence of medica-
tion overuse [10]. This a very restricted definition and the
number of the patients fulfilling this criteria is low. The
majority of patients suffering frequent migraines are
patients that usually have a past history of episodic
migraine of more than 15–20 years of evolution, that typ-
ically began in their teens or 20s. As the headaches
increase in frequency over months or years, the associat-
ed symptoms of nausea, photophobia and phonophobia
become less severe and less frequent. Headache may have
clinical characteristics of migraine or of tension-type
headache (TTH). When the migraine attack appears, it has
less associated symptoms. Other migraine features may
persist. Familial history of migraine is often present.
Patients often continue to have typical migraine attacks,
but in some cases their migraine headaches disappear
completely. Usually it develops in the setting of analgesic
overuse, but in 20%–30% of cases it may occur without it.
Patients with medication overuse have a constant low-
grade headache, which is aggravated hours after the use of
the substance, and only partially alleviated with the con-
sumption of repeated doses of medication. These CDH
patients have a significant impairment of their health-
related quality of life [11].
Chronic tension-type headache
CDH may also develop in patients who have a history of
ETTH. Headache is more often diffuse or bilateral, fre-
quently involving the posterior aspect of the head and
neck. These patients do not have migraine features or pre-
vious or coexistent episodic migraine. Some mild associ-
ated symptoms, such as mild nausea, photophobia or
phonophobia may be compatible with the diagnosis of
CTTH. It may also appear associated with or without
medication overuse.
In population-based studies, CTTH appears to be the
most frequent type of daily headache, even though little is
known about its nature and what the syndrome actually
represents. Some recent studies support that, at least in
some part, CTTH is a disorder of the central nervous sys-
tem with probable sensitisation of second-order trigeminal
neurons and some peripheral component [12]. It has also
been suggested that genetic factors influence the risk of
CTTH [8]. But other causes of non-genetic familial aggre-
gation or gene-environmental interactions may influence
these findings.
New daily persistent headache
Patients with NDPH develop it in the absence of a previous
history of episodic migraine or ETTH [10]. It is a rare type
of CDH in which the onset of headache is usually abrupt,
occurring in a few days. Some patients remember the exact
day the headache started. These patients are generally
younger than those with other types of CDH, so the pro-
portion of patients diagnosed with NDPH is much higher in
children and adolescent CDH series than in adults [13].
Commonly headache is similar to TTH, but there is no
progressive evolution from a previous headache. NDPH is
likely to be a very heterogeneous disorder. It has been
related to a post-viral syndrome or to an unknown chron-
ic infection [13]. In our personal experience, even when
some patients referred an infection previous to the devel-
opment of the headache, we could not serologically de-
monstrate it.
NDPH has been included in the new classification
under the chapter of Other primary headaches.
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